Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02859402 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

Study acronym: RRTCLAlloSCT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 18, 2022 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2024 to Dec 2025
    • Study completion date: Dec 2026 to Dec 2027
    v6
  2. Primary completion date: Dec 2019 to Dec 2024
    • Study completion date: Dec 2021 to Dec 2026
    v5
  3. Eligibility criteria revisedv4
  4. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date: Sep 2016 to Dec 2016
    • Primary completion date: Sep 2019 to Dec 2019
    • Study completion date: Sep 2021 to Dec 2021
    • Site details revised at 2 of 2 sites
  5. Collaborators: 2 to 1v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.
Trial Details
NCT Number NCT02859402
Lead Sponsor Keimyung University Dongsan Medical Center
Collaborators: Otsuka Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell
Related terms Lymphoma, Extranodal NK-T-Cell, Lymphoma, T-Cell, Recurrence
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov